Chondrocytes play a role in the development of rheumatoid arthritis via TMEM147-mediated NF-κB activation.
We previously reported that the co-activation of NF-κB and STAT3 in non-immune cells including synovial fibroblasts enhances the expression of NF-κB target genes, playing a role in chronic inflammation including rheumatoid arthritis (RA). Here we examined the role of NF-κB activation in chondrocytes to understand the pathogenesis of RA. Furthermore, we investigated TMEM147 as a representative NF-κB activator in chondrocytes. Clinical samples from RA patients were analyzed by immunohistochemistry. Samples from polydactyly patients served as a control. The functional contribution of chondrocytes and TMEM147 to arthritis was examined in several mouse RA models. In vitro experiments including qPCR, RNA interference, immunoprecipitation and confocal microscopy were performed to investigate the mechanism of action of TMEM147 in chondrocytes. Samples from RA patients and from the RA models showed co-activation of NF-κB and STAT3 in chondrocytes (p<0.001). This co-activation induced a synergistic expression of NF-κB targets in vitro (p<0.01). Chondrocyte-specific deletion of STAT3 significantly suppressed the development of cytokine-induced RA (p<0.01). TMEM147 was highly expressed in chondrocytes from RA patients and the RA models. Gene silencing of TMEM147 or anti-TMEM147 antibody treatment inhibited the cytokine-mediated activation of NF-κB in vitro (p<0.01) and suppressed the cytokine-induced RA in vivo (p<0.01). Mechanistically, TMEM147 molecules acted as a scaffold protein for a NF-κB complex that included breakpoint cluster region and casein kinase 2 to enhance NF-κB activity. These results suggest that chondrocytes play a role in the development of RA via TMEM147-mediated NF-κB activation and provide a novel therapeutic strategy for RA.